Pathogenic role of mitochondrial DNA mutations in heart failure: clinical features, mechanisms, and therapeutic prospects
Frontiers in Cardiovascular Medicine · 01.04.2026 · 13
DOI: 10.3389/fcvm.2026.1781927 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 01.04.2026. Verfasst von Mingyang Ni und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardiodynamics and Assistive Tech Group, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Wuhan Joint Laboratory (China-Ser…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Heart failure (Heart failure, HF) is a complex clinical syndrome caused by any abnormality in the structure or function of the heart, resulting in impaired ventricular filling or ejection capacity, with mitochondrial dysfunction recognized as one of the key pathological foundations. In recent years, numerous studies have demonstrated that mitochondrial DNA (mtDNA) mutations play a significant role in cardiomyopathy and HF; however, systematic understanding of their modes of action in disease progression remains limited. Most studies have attributed the pathogenic effects of mtDNA mutations to impaired energy metabolism, emphasizing the consequences of defective oxidative phosphorylation and insufficient ATP production on myocardial function. Emerging evidence, however, indicates that mtDNA mutations also contribute to the development and progression of HF by inducing reactive oxygen species accumulation, disrupting mitochondrial structural and dynamic homeostasis, and activating innate immune inflammatory signaling pathways. Furthermore, variations in mtDNA mutation load and heteroplasmy levels constitute an important molecular basis for the diverse clinical phenotypes of HF, although the underlying mechanisms have yet to be systematically integrated. This review comprehensively summarizes the pathogenic mechanisms of cardiac mtDNA mutations and their heteroplasmy in HF, with particular emphasis on the intrinsic links among mitochondrial metabolic reprogramming, oxidative stress, immune activation, and myocardial remodeling, and outlines potential diagnostic and therapeutic strategies based on mitochondrial dysfunction and mtDNA stability.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiodynamics and Assistive Tech Group, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Wuhan Joint Laboratory (China-Serbia) of Biomedical and Health Science, School of Life and Health Scien…
- Hubei Provincial Enterprise Technology Center, Wuhan Vickor Medical Technology Co., Ltd., Wuhan, China.
Zitieren
APA
Ni, M., Zheng, A., Zheng, H., Jia, W., Wang, Y., Peng, Y., Yao, C., Wei, Y., Wang, X., & Kang, S. (2026). Pathogenic role of mitochondrial DNA mutations in heart failure: clinical features, mechanisms, and therapeutic prospects. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1781927
Vancouver
Ni M, Zheng A, Zheng H, Jia W, Wang Y, Peng Y, et al. Pathogenic role of mitochondrial DNA mutations in heart failure: clinical features, mechanisms, and therapeutic prospects. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1781927
BibTeX
@article{Ni2026,
author = {Ni, Mingyang and Zheng, Aijia and Zheng, Hang and Jia, Wenqing and Wang, Yuansheng and Peng, Yuqing and Yao, Chenguang and Wei, Yanhong and Wang, Xueli and Kang, Sini},
title = {Pathogenic role of mitochondrial DNA mutations in heart failure: clinical features, mechanisms, and therapeutic prospects},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1781927}
}
EUVIMED